ExpressCells (Biotechnology) — Funding, Investors & Signals 2026

ExpressCells

Using genetic engineering to create knock-in cell lines for biological research

Founded 2018

Philadelphia, United States 2-10 employees Series Unknown Total: $1.79M Biotechnology

ExpressCells is a biotechnology startup that is revolutionizing biological research with its genetic engineering technology. The company's slogan, "Using genetic engineering to create knock-in cell lines for biological research," encapsulates its mission perfectly. ExpressCells addresses a crucial need in the field of biological research, where the process of creating genetically altered cell lines for studying specific proteins has been hindered by time-consuming methods and limitations in modifications. The company's proprietary technology leverages CRISPR and a genetic vector system to produce custom cells for research a stunning 4X faster than the current processes. Moreover, these engineered cells have the ability to replicate diseases or showcase proteins in multiple colors without being killed for study purposes. This breakthrough not only streamlines research processes but also opens up new possibilities for studying drug interactions and protein behavior within cells. Founded in 2018 and headquartered in the United States, ExpressCells recently secured a $590.50K Venture Round investment on 23 October 2020. The investment was backed by notable venture capital firms including Tech Coast Angels, Robin Hood Ventures, Berkeley Angel Network, and MIT Alumni Angels of Northern California. As the company continues to make strides in biotechnology, its innovative approach and strong investor backing position ExpressCells as a promising player in the field of genetic engineering for biological research. Follow their journey on Twitter at https://twitter.com/expresscells.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	••••••	4		23 Oct 2020
Series A	••••••	3	•••• ••••	01 Jul 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

••••••

23 Oct 2020

Series A

••••••

•••• ••••

01 Jul 2019

FAQ About ExpressCells

Using genetic engineering to create knock-in cell lines for biological research

ExpressCells was founded in 2018.

ExpressCells is headquartered in Philadelphia, United States.

ExpressCells operates in the following industries: Biotechnology.

ExpressCells has approximately 2-10 employees.

ExpressCells has completed 2 funding rounds, raising a total of $1.79M. The latest funding stage is Series Unknown.

Top alternatives and competitors to ExpressCells include Stembio Cell and Tissue Technologies Inc., ViaCyte, Aldagen, Inc, acCELLerate, SAL Scientific Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

ExpressCells and Stembio Cell and Tissue Technologies Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

ExpressCells

General Information

Track ExpressCells

Discover More

About ExpressCells

Funding Rounds & Investors (2)

ExpressCells Alternatives & Competitors

FAQ About ExpressCells

Don't just browse. Track.